CASE STUDY: EVOLUTION IN THE MEDICAL DEVICE SUPPLY CHAIN Cardinal Health and DHL discuss trust and partnership in logistics and back office
With
Steve Thompsett, CEO
DHL Supply Chain Australia and New Zealand
Michael Gardner,
(Former) VP Life Sciences & Healthcare
DHL Supply Chain Australia
Shane McCormack,
Senior Manager Supply Chain
Cardinal Health
Australian Health Journal segment
Filmed in Sydney | April 2025
Supply chain and logistics involve managing products globally, from manufacturing to distribution. This includes international shipping via air and sea, storing products in temperature-controlled warehouses, and delivering them to pharmacies, medical wholesalers, and hospitals within the domestic market.
Michael Gardner, (Former) VP Life Sciences & Healthcare, DHL Supply Chain Australia spoke to Australian Health Journal about the medical device industry being particularly complex; onboarding a new customer at DHL supply chain demands thorough preparation. This process involves understanding the customer’s operations and the lifecycle of their products, from their arrival at the warehouse to their use in patient care. Insight into the customer’s expectations is crucial to ensure seamless operations.
For Cardinal Health, a global manufacturer and distributor of medical products, the process begins when products arrive in Australia and are cleared by customs before being stored at their Sydney warehouse. From here, they fulfil orders for various clients, including hospitals and wholesalers, supported by DHL’s logistics services.
In this case study, Australian Health Journal was given the opportunity to talk to both the logistics provider and the end medical technology client in what is an evolving medical device supply chain.
Challenges in Australia include a limited manufacturing workforce and the distances to raw material sources, with all imported products being finished goods. Compliance with safety and regulatory standards is essential. In addition to logistics, DHL provides value-added services like equipment repairs and a 4PL service, which includes customer service support and accounts receivable, enhancing efficiency for Cardinal Health.
Credit: MedTech24 Conference, hosted by Medical Technology Association of Australia (MTAA) in Sydney, October 2024.
Source: Written by AUDIENCED, with use of generative AI on transcript
-
Practising to top scope of urology practice, advancing treatment & patient care through research
Michael is a urology nurse practitioner with a special interest in prostate cancer survivorship, and has worked in urology for the past ten years. Michael has completed the Prostate Nursing Care course at Latrobe University, Graduate Certificate of Health with a specialisation in Scheduled Medicines (USQ), and the Master of Nursing (Flinders) to become a Nurse Practitioner in 2024.
As a Urology Nurse Practitioner he divides his time between the Australian Prostate Centre and Western Urology.
-
Pathology technology at a crossroads
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
– Pathology Technology Australia’s key priorities in the coming years
– Current local capability in pathology technology compared to other countries
– How the health system supports change and adoption of pathology technology
– How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
– Observations in the Strengthening Medicare Taskforce ReportIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
